This work evaluates the radiological risk that patients treated with I for differentiated thyroid cancer could present to relatives and occupationally exposed workers. Recently, the International Atomic Energy Agency issued document K9010241, which recommends that patient discharge from the hospital must be based on the particular status of each patient. This work measures effective dose received by caregivers of patients treated with I at the Instituto Nacional de Cancerología, Mexico City. Thermoluminescent dosimeters were carried during a 15-d period by 40 family caregivers after patient release from hospital. Relatives were classified into two groups, ambulatory and hospitalized, according to the release mode of the patient, and three categories according to the individual patient home and transport facilities. Categories A, B, and C were defined going from most to least adequate concerning public exposure risk. Measurements were performed for 20 family caregivers in each group. The effective dose received by all caregivers participating in this study was found to be less than 5 mSv, the recommended limit per event for caregivers suggested by ICRP 103. In addition, 70 and 90% of ambulatory and hospitalized groups, respectively, received doses lower than 1 mSv. Caregivers belonging to category C, with home situations that are not appropriate for immediate release, received the highest average doses; i.e., 2.2 ± 1.3 and 3.1 ± 1.0 mSv for hospitalized and ambulatory patients, respectively. Results of this work have shown that the proper implementation of radiation protection instructions for relatives and patients can reduce significantly the risk that differentiated thyroid cancer patients treated with I can represent for surrounding individuals. The results also stress the relevance of the patient's particular lifestyle and transport conditions as the prevailing factors related to the dose received by the caregiver. Therefore, the patient's status should be the criterion used to decide his/her release modality. This work provides support to recommend the implementation of the "patient specific release criteria" in accordance with ICRP 94, IAEA Safety Report No. 63, and IAE document K9010241 A for patients treated with radiopharmaceuticals.
Aim: To compare the dose to organs at risk with free breathing (FB) or voluntary breath-hold (VBH) during radiotherapy of patients with left sided breast cancer. Background: Radiotherapy reduces the risk of breast-cancer-specific mortality but the effects on other organs increase non-cancer-specific mortality. Radiation exposure to the heart, in particular in patients with left sided breast cancer, can be reduced by breath hold methods that increase the distance between the heart and the radiation field. Materials and Methods: Three-dimensional conformal radiotherapy (3D-CRT) dose plans for the left breast and organs at risk including the heart, left anterior descending coronary artery (LAD) and ipsilateral lung were compared with FB and VBH in ten patients with left sided breast cancer.Results: The mean doses to the heart and LAD were reduced by 50.4 % (p < 0.001) and 58.8 % (p = 0.006), respectively, in VBH relative to FB. The mean dose to the ipsilateral lung was reduced by 13.8 % (p = 0.11) in VBH relative to FB. The planning target volume (PTV) coverage was at least 95 % in both FB and VBH (p = 0.78). Conclusion:The VBH technique significantly reduces the dose to organs at risk in 3D-CRT treatment plans of left sided breast cancer.
To measure the out-of -field mean photon energy and dose imparted by the secondary radiation field generated by 6 MV and 6 MV FFF beams using TLD-300 and TLD-100 dosimeters and to use the technique to quantify the contributions from the different sources that generate out-of -field radiation. Methods: The mean photon energy and the dose were measured using the TLD-300 glow curve properties and the TLD-100 response, respectively. The TLD-300 glow curve shape was energy-calibrated with gamma rays from 99m Tc, 18 F, 137 Cs, and 60 Co sources, and its energy dependence was quantified by a parameter obtained from the curve deconvolution. The TLD-100 signal was calibrated in absorbed dose-to-water inside the primary field. Dosimeters were placed on the linac head, and on the surface and at 4.5 cm depth in PMMA at 1-15 cm lateral distances from a 10 × 10 cm 2 field edge at the isocenter plane. Three configurations of dosimeters around the linac were defined to identify and quantify the contributions from the different sources of out-of -field radiation. Results: Typical energies of head leakage were about 500 keV for both beams. The mean energy of collimator-scattered radiation was equal to or larger than 1250 keV and, for phantom-scattered radiation, mean photon energies were 400 keV for the 6 MV and 300 keV for the 6 MV FFF beam. Relative uncertainties to determine mean photon energy were better than 15% for energies below 700 keV, and 40% above 1000 keV. The technique lost its sensitivity to the incident photon energy above 1250 keV. On the phantom surface and at 1-15 cm from the field edge, 80%-90% of out-of -field dose came from scattering in the secondary collimator. At 4.5 cm deep in the phantom and 1-5 cm from the field edge, 50%-60% of the out-of -field dose originated in the phantom. At the points of measurement, the head leakage imparted less than 0.1% of the dose at the isocenter. The 6 MV FFF beam imparted 8-36% less out-of -field dose than the 6 MV beam. These energy results are consistent with general Monte Carlo simulation predictions and show excellent agreement with simulations for a similar linac. The measured out-of -field doses showed good agreement with independent evaluations. Conclusions: The out-of -field mean photon energy and dose imparted by the secondary radiation field were quantified by the applied TLD-300/TLD-100 method. The main sources of out-of -field dose were identified and quantified using three configurations of dosimeters around the linac. This technique could be of value to validate Monte Carlo simulations where the linac head design, configuration, or material composition are unavailable.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.